Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?
Melissa PilewskieMichelle StempelHope RosenfeldAnne EatonKimberly J VanZeeMonica MorrowPublished in: Annals of surgical oncology (2016)
Among LORIS-eligible women, 20 % had invasive carcinoma at surgical excision that was heterogeneous in grade, size, and receptor status. Information gained from surgical excision influenced receipt of adjuvant radiation and endocrine therapy in most patients, and indicated benefit from chemotherapy in 18 % of patients. Surgical excision is warranted until additional risk stratification is available to identify a cohort of DCIS patients at lower risk for clinically significant synchronous invasive carcinoma.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- clinical trial
- healthcare
- early stage
- prognostic factors
- radiation therapy
- metabolic syndrome
- study protocol
- patient reported outcomes
- adipose tissue
- skeletal muscle
- patient reported
- insulin resistance
- radiation induced
- health information
- locally advanced
- open label